PERTH, Australia – Adelaide, Australia-based Bionomics Inc. reported another trial failure with its lead compound, BNC-210, in elderly patients with agitation, but it is still clinging on to hopes that the compound will show a clinical benefit for post-traumatic stress disorder (PTSD).
PERTH, Australia – Adelaide, Australia-based Bionomics Inc. reported another trial failure with its lead compound, BNC-210, in elderly patients with agitation, but it is still clinging on to hopes that the compound will show a clinical benefit for post-traumatic stress disorder (PTSD).
PHILADELPHIA – Shanghai-based Epimab Biotherapeutics Inc. raised $74 million in a series B round to advance its phase I/II lead candidate, EMB-01, and expand its pipeline into immuno-oncology.
PHILADELPHIA –The escalating trade war between the United States and China dominated most of the discussion during the China Summit meeting at the Biotechnology Innovation Organization' (BIO) international convention.
PERTH, Australia – After a AU$2 million (US$1.4 million) capital raise in April, Perth-headquartered Pharmaust Ltd. will advance its lead compound monepantel into phase I trials in humans.
PHILADELPHIA – This year's Australian delegation saw the most impressive participation to date at the Biotechnology Innovation Organization's (BIO) 2019 conference, with more than 150 Australian companies participating as well as numerous government representatives.
PERTH, Australia – After a AU$2 million (US$1.4 million) capital raise in April, Perth-headquartered Pharmaust Ltd. will advance its lead compound monepantel into phase I trials in humans.
PHILADELPHIA – This year's Australian delegation saw the most impressive participation to date at the Biotechnology Innovation Organization's (BIO) 2019 conference, with more than 150 Australian companies participating as well as numerous government representatives.
